{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T18:13:14Z","timestamp":1778004794038,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Boehringer Ingelheim"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12325-020-01384-0","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T22:02:41Z","timestamp":1590184961000},"page":"3246-3264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach"],"prefix":"10.1007","volume":"37","author":[{"given":"Wim A.","family":"Wuyts","sequence":"first","affiliation":[]},{"given":"Spyridon","family":"Papiris","sequence":"additional","affiliation":[]},{"given":"Effrosyni","family":"Manali","sequence":"additional","affiliation":[]},{"given":"Maritta","family":"Kilpel\u00e4inen","sequence":"additional","affiliation":[]},{"given":"Jesper R\u00f8mhild","family":"Davidsen","sequence":"additional","affiliation":[]},{"given":"Jelle","family":"Miedema","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Robalo-Cordeiro","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Morais","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9578-743X","authenticated-orcid":false,"given":"Maite","family":"Art\u00e9s","sequence":"additional","affiliation":[]},{"given":"Guus","family":"Asijee","sequence":"additional","affiliation":[]},{"given":"David","family":"Cendoya","sequence":"additional","affiliation":[]},{"given":"St\u00e9phane","family":"Soulard","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"issue":"150","key":"1384_CR1","doi-asserted-by":"publisher","first-page":"180076","DOI":"10.1183\/16000617.0076-2018","volume":"27","author":"V Cottin","year":"2018","unstructured":"Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076.","journal-title":"Eur Respir Rev"},{"issue":"6","key":"1384_CR2","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1384_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjresp-2017-000212","volume":"4","author":"KR Flaherty","year":"2017","unstructured":"Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017;4(1):1\u20137.","journal-title":"BMJ Open Respir Res"},{"issue":"5","key":"1384_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.00692-2018","volume":"51","author":"AU Wells","year":"2018","unstructured":"Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ. What\u2019s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51(5):1\u201312.","journal-title":"Eur Respir J"},{"key":"1384_CR5","doi-asserted-by":"crossref","unstructured":"Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019, 1\u201310.","DOI":"10.1080\/03007995.2019.1647040"},{"issue":"150","key":"1384_CR6","doi-asserted-by":"publisher","first-page":"180077","DOI":"10.1183\/16000617.0077-2018","volume":"27","author":"AL Olson","year":"2018","unstructured":"Olson AL, Gifford AH, Inase N, Fern\u00e1ndez P\u00e9rez ER, Suda T. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev. 2018;27(150):180077.","journal-title":"Eur Respir Rev"},{"key":"1384_CR7","doi-asserted-by":"crossref","unstructured":"Olson A, Hartmann N, Schlenker-Herceg R, Wallace L. Prevalence of progressive fibrosing interstitial lung disease. ERS Int Congr. 2018;PA3030.","DOI":"10.1183\/13993003.congress-2018.PA3030"},{"issue":"2","key":"1384_CR8","doi-asserted-by":"publisher","first-page":"1602419","DOI":"10.1183\/13993003.02419-2016","volume":"50","author":"B Duchemann","year":"2017","unstructured":"Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, Sanyal S, Brillet P-Y, Brauner M, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J. 2017;50(2):1602419.","journal-title":"Eur Respir J"},{"issue":"8","key":"1384_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.rmed.2009.03.001","volume":"103","author":"A Karakatsani","year":"2009","unstructured":"Karakatsani A, Papakosta D, Rapti A, Antoniou KM, Dimadi M, Markopoulou A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med. 2009;103(8):1122\u20139.","journal-title":"Respir Med"},{"key":"1384_CR10","first-page":"114s","volume":"32","author":"MJ Thomeer","year":"2001","unstructured":"Thomeer MJ, Costabe U, Rizzato G, Poletti V, Demedts M. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J Suppl. 2001;32:114s\u20138s.","journal-title":"Eur Respir J Suppl"},{"issue":"1","key":"1384_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12931-017-0621-y","volume":"18","author":"M Kreuter","year":"2017","unstructured":"Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res. 2017;18(1):139.","journal-title":"Respir Res"},{"key":"1384_CR12","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0075-2018","author":"JJ Swigris","year":"2018","unstructured":"Swigris JJ, Brown KK, Abdulqawi R, Buch K, Dilling DF, Koschel D, et al. Patients\u2019 perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018. https:\/\/doi.org\/10.1183\/16000617.0075-2018.","journal-title":"Eur Respir Rev"},{"issue":"7","key":"1384_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s40273-018-0631-8","volume":"36","author":"A Diamantopoulos","year":"2018","unstructured":"Diamantopoulos A, Wright E, Vlahopoulou K, Cornic L, Schoof N, Maher TM. The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review. Pharmacoeconomics. 2018;36(7):779\u2013807.","journal-title":"Pharmacoeconomics"},{"issue":"150","key":"1384_CR14","doi-asserted-by":"publisher","first-page":"180076","DOI":"10.1183\/16000617.0078-2018","volume":"27","author":"C Holtze","year":"2018","unstructured":"Holtze C, Flaherty K, Kreuter M, Luppi F, Moua T, Vancheri C, et al. Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076.","journal-title":"Eur Respir Rev"},{"issue":"18","key":"1384_CR15","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"2","key":"1384_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1183\/09031936.00159709","volume":"37","author":"JW Song","year":"2011","unstructured":"Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356\u201363.","journal-title":"Eur Respir J"},{"issue":"150","key":"1384_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/16000617.0071-2018","volume":"27","author":"M Kolb","year":"2018","unstructured":"Kolb M, Bondue B, Pesci A, Miyazaki Y, Song JW, Bhatt NY, et al. Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):1\u20138.","journal-title":"Eur Respir Rev"},{"issue":"9","key":"1384_CR18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708\u201319.","journal-title":"Lancet Respir Med"},{"key":"1384_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30341-8","author":"TM Maher","year":"2019","unstructured":"Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2019. https:\/\/doi.org\/10.1016\/S2213-2600(19)30341-8.","journal-title":"Lancet Respir Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01384-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01384-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01384-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T17:29:45Z","timestamp":1666632585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01384-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01384-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]},"assertion":[{"value":"15 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}